{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:30:42Z","timestamp":1774355442048,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Psoriasis is a systemic immune-mediated disease with ocular involvement. While biologic therapies reduce cardiovascular and musculoskeletal comorbidities, their impact on ocular health is not well characterised. We aimed to assess whether biologic therapy is associated with reduced ocular disease risk in psoriasis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/methods<\/jats:title>\n                    <jats:p>We performed a large-scale, retrospective cohort study using the TriNetX Global Collaborative Network (&gt;160 million patients worldwide). Adults with psoriasis initiating biologic therapy were compared with those receiving non-biologic systemic treatments. Cohorts were matched 1:1 by propensity scoring for demographic and clinical variables. Sixty-eight ocular outcomes were assessed over 6 to 120 months. Hazard ratios (HRs) were estimated using proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 30,911 biologic-treated and 35,832 non-biologic-treated patients with psoriasis, biologic therapy was consistently associated with reduced risk of ocular surface and corneal inflammation. The strongest associations were seen for dry eye disease (mean HR\u2009=\u20090.55, 95% confidence interval [CI; 0.42, 0.66],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0007), conjunctivitis (mean HR\u2009=\u20090.71, 95% CI [0.59, 0.86],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), and keratitis (mean HR\u2009=\u20090.40, 95% CI [0.3, 0.56],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0007). These lower-risk associations were evident from 6 months and remained observable in the 10-year analysis window. No consistent reduction was observed for retinal or vitreous disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Biologic therapy in psoriasis was associated with a lower risk of ocular surface disease. These observational findings may inform interdisciplinary management and consideration of ocular outcomes in treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04274-x","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:54:47Z","timestamp":1770274487000},"page":"676-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologic therapy is associated with reduced ocular disease in psoriasis: a real-world study"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6500-2946","authenticated-orcid":false,"given":"Shoham","family":"Kubovsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natan","family":"Lishinsky-Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itay","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Ramot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0043-4354","authenticated-orcid":false,"given":"Jaime","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"4274_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/09273948.2025.2477194","volume":"33","author":"A Leszy\u0144ska","year":"2025","unstructured":"Leszy\u0144ska A, Koz\u0142owska D, Ba\u0142oniak J, Linke J, Bacho\u0144 E, Doligalska M, et al. Ocular Manifestations in selected dermatological disorders: a narrative review. Ocul Immunol Inflamm. 2025;33:1023\u201330. https:\/\/doi.org\/10.1080\/09273948.2025.2477194.","journal-title":"Ocul Immunol Inflamm"},{"key":"4274_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/09273948.2025.2459710","volume":"33","author":"AG Almutairi","year":"2025","unstructured":"Almutairi AG, Aloraini LI, Almutairi RR, Alfaqih AA, Alruwaili SA, Aljefri S. Ocular manifestations of psoriasis: a systematic review. Ocul Immunol Inflamm. 2025;33:827\u201335. https:\/\/doi.org\/10.1080\/09273948.2025.2459710.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"4274_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-025-00486-6","volume":"15","author":"AC Faneli","year":"2025","unstructured":"Faneli AC, Amaral DC, Menezes IR, Marques GN, Guedes J, Brazuna R, et al. Ocular complications in psoriatic patients: a systematic review and meta-analysis. J Ophthalmic Inflamm Infect. 2025;15(1):29. https:\/\/doi.org\/10.1186\/s12348-025-00486-6.","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"5","key":"4274_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1159\/000522167","volume":"238","author":"PC Wu","year":"2022","unstructured":"Wu PC, Ma SH, Huang YY, Chang JY, Chang YT, Dai YX. Psoriasis and dry eye disease: a systematic review and meta-analysis. Dermatology. 2022;238(5):876\u201385. https:\/\/doi.org\/10.1159\/000522167.","journal-title":"Dermatology"},{"key":"4274_CR5","doi-asserted-by":"publisher","first-page":"105485","DOI":"10.1016\/j.ebiom.2024.105485","volume":"111","author":"K Kridin","year":"2025","unstructured":"Kridin K, Bieber K, Vorobyev A, Moderegger EL, Olbrich H, Ludwig MA, et al. Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis. EBioMedicine. 2025;111:105485. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105485.","journal-title":"EBioMedicine"},{"issue":"4","key":"4274_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/14712598.2024.2337242","volume":"24","author":"S Boskovic","year":"2024","unstructured":"Boskovic S, Borriello S, D'ascenzo F, Sciamarrelli N, Rosset F, Mastorino L, et al. Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk. Expert Opin Biol Ther. 2024;24(4):217\u20139. https:\/\/doi.org\/10.1080\/14712598.2024.2337242.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"4274_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","volume":"11","author":"A Watad","year":"2024","unstructured":"Watad A, Zabotti A, Patt YS, Gendelman O, Dotan A, Ben-Shabat N, et al. From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis. Rheumatol Ther. 2024;11(4):963\u201376. https:\/\/doi.org\/10.1007\/s40744-024-00680-3.","journal-title":"Rheumatol Ther"},{"key":"4274_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40259-025-00705-5","volume":"39","author":"S Yu","year":"2025","unstructured":"Yu S, Huo AP, Wang YH, Wei JCC. Interleukin-23 versus Interleukin-17 inhibitors in preventing incidental psoriatic arthritis in patients with psoriasis: a real-world comparison from the TriNetX US collaborative network. BioDrugs. 2025;39:297\u2013306. https:\/\/doi.org\/10.1007\/s40259-025-00705-5.","journal-title":"BioDrugs"},{"key":"4274_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.exer.2013.08.013","volume":"117","author":"SC Pflugfelder","year":"2013","unstructured":"Pflugfelder SC, Corrales RM, de Paiva CS. T helper cytokines in dry eye disease. Exp Eye Res. 2013;117:118\u201325. https:\/\/doi.org\/10.1016\/j.exer.2013.08.013.","journal-title":"Exp Eye Res"},{"issue":"3","key":"4274_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/mi.2009.5","volume":"2","author":"CS De Paiva","year":"2009","unstructured":"De Paiva CS, Chotikavanich S, Pangelinan SB, Pitcher JD, Fang B, Zheng X, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2(3):243\u201353. https:\/\/doi.org\/10.1038\/mi.2009.5.","journal-title":"Mucosal Immunol"},{"key":"4274_CR11","doi-asserted-by":"publisher","unstructured":"Zarzuela JC, Reinoso R, Armentia A, Enr\u00edquez-de-Salamanca A, Corell A. Conjunctival intraepithelial lymphocytes, lacrimal cytokines and ocular commensal microbiota: analysis of the three main players in allergic conjunctivitis. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.911022.","DOI":"10.3389\/fimmu.2022.911022"},{"issue":"1","key":"4274_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cyto.2010.08.009","volume":"53","author":"JT Kim","year":"2011","unstructured":"Kim JT, Lee SH, Chun YS, Kim JC. Tear cytokines and chemokines in patients with Demodex blepharitis. Cytokine. 2011;53(1):94\u20139. https:\/\/doi.org\/10.1016\/j.cyto.2010.08.009.","journal-title":"Cytokine"},{"issue":"1","key":"4274_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02713683.2018.1519834","volume":"44","author":"KB Garbutcheon-Singh","year":"2019","unstructured":"Garbutcheon-Singh KB, Carnt N, Pattamatta U, Samarawickrama C, White A, Calder V. A review of the cytokine IL-17 in ocular surface and corneal disease. Curr Eye Res. 2019;44(1):1\u201310. https:\/\/doi.org\/10.1080\/02713683.2018.1519834.","journal-title":"Curr Eye Res"},{"key":"4274_CR14","doi-asserted-by":"publisher","first-page":"6628923","DOI":"10.1155\/2021\/6628923","volume":"2021","author":"H Zhang","year":"2021","unstructured":"Zhang H, Cao X, Liu Y, Wang P, Li X. Tear levels of inflammatory cytokines in keratoconus: a meta-analysis of case-control and cross-sectional studies. Biomed Res Int. 2021;2021:6628923 https:\/\/doi.org\/10.1155\/2021\/6628923.","journal-title":"Biomed Res Int"},{"issue":"14","key":"4274_CR15","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1167\/iovs.16-20187","volume":"57","author":"T Yamaguchi","year":"2016","unstructured":"Yamaguchi T, Higa K, Suzuki T, Nakayama N, Yagi-Yaguchi Y, Dogru M, et al. Elevated cytokine levels in the aqueous humor of eyes with bullous keratopathy and low endothelial cell density. Invest Ophthalmol Vis Sci. 2016;57(14):5954\u201362. https:\/\/doi.org\/10.1167\/iovs.16-20187.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"4274_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/1440-1681.13141","volume":"46","author":"Y Ren","year":"2019","unstructured":"Ren Y, Qi Y, Su X. Th17 cells in glaucoma patients promote Ig production in IL-17A and IL-21-dependent manner. Clin Exp Pharmacol Physiol. 2019;46(10):875\u201382. https:\/\/doi.org\/10.1111\/1440-1681.13141.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"4274_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000484907","volume":"44","author":"J Chen","year":"2017","unstructured":"Chen J, Wang W, Li Q. Increased Th1\/Th17 responses contribute to low-grade inflammation in age-related macular degeneration. Cellular Physiology and Biochemistry. 2017;44(1):357\u201367. https:\/\/doi.org\/10.1159\/000484907.","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"15","key":"4274_CR18","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.7150\/ijbs.49890","volume":"16","author":"W Tan","year":"2020","unstructured":"Tan W, Zou J, Yoshida S, Jiang B, Zhou Y. The role of inflammation in age-related macular degeneration. Int J Biol Sci. 2020;16(15):2989\u20133001. https:\/\/doi.org\/10.7150\/ijbs.49890.","journal-title":"Int J Biol Sci"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04274-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:38:46Z","timestamp":1774352326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04274-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4274"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04274-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YR received speaker honoraria, consultancy fees or travel support from Pfizer, AbbVie, Novartis, Janssen, Johnson & Johnson, Sanofi, BI, Neopharm, Dexcel Pharma, Taro, BMS, Takeda and Lilly. The other authors have nothing to declare. The authors report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}